Medicilon Assists Huaota's CD73-targeting ADC approved for clinical use in US
- Reads 1
- Votes 0
- Parts 1
- Time <5 mins
- Reads 1
- Votes 0
- Parts 1
- Time <5 mins
Ongoing, First published Nov 23, 2023
Recently, Shanghai Huaota Biopharmaceutical Co., Ltd. (Huaota) received a notification from the US FDA, agreeing that the third-generation antibody drug conjugate (ADC) project HB0052 developed by the company targeting the CD73 antigen will enter clinical trials. This is the first antibody conjugate drug project approved by Huaota Biotech to enter clinical trials by the FDA.All Rights Reserved
Sign up to add Medicilon Assists Huaota's CD73-targeting ADC approved for clinical use in US to your library and receive updates
or
You may also like
You may also like
